Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled adjunctive KarXT study for acute mania in bipolar I disorder
MOH_2025-12-17_015549Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in bipolar I disorder and mania comparing Cobenfy + mood stabilizer with Placebo + mood stabilizer (2 arms). Started Dec 2025; status: recruiting.
02
Drugs
trospium
03
Conditions
bipolar I disordermania
Beyond the preview
Go deeper on MOH_2025-12-17_015549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-12-17_015549.